Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells.
|
| Abstract |
Clarithromycin (CAM) is a macrolide antibiotic that is widely used in the treatment of respiratory tract infections, sexually transmitted diseases and infections caused by the Helicobacter pylori and Mycobacterium avium complex. Recent studies showed that CAM was highly effective against multiple myeloma (MM) when used in combination with immunomodulatory drugs and dexamethasone. However, the related mechanism is still unknown. As 3 immunomodulatory agents are all effective in the respective regimen, we postulated that CAM might enhance the effect of immunomodulatory drugs. We evaluated the interaction effects of CAM and thalidomide on myeloma cells. Taking into consideration that thalidomide did not affect the proliferation of myeloma cells in vitro, we cocultured myeloma cells with peripheral blood monocytes and evaluated the effects of CAM and thalidomide on the cocultured cell model. Data showed that thalidomide and CAM synergistically inhibited the proliferation of the cells. On this same model, we also found that thalidomide and CAM synergistically decreased the secretion of tumor necrosis factor-α and interleukin-6. This might be caused by the effect of the 2 drugs on inhibiting the activation of ERK1/2 and AKT. These data suggest that the efficacy of CAM against MM was partly due to its synergistic action with the immunomodulatory agents.
|
|---|---|
| Authors | Xu-Hua Qiu, Jing-Jing Shao, Jian-Gang Mei, Han-Qing Li, Hong-Qin Cao |
| Journal | Acta haematologica (Acta Haematol) Vol. 135 Issue 2 Pg. 103-9 ( 2016) ISSN: 1421-9662 [Electronic] Switzerland |
| PMID | 26505646 (Publication Type: Journal Article) |
| Copyright | © 2015 S. Karger AG, Basel. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!